article thumbnail

Osteoporosis market expected to reach $17.9bn across 7MM by 2033

Pharmaceutical Technology

The osteoporosis market is expected to grow at a compound annual growth rate of 5.4% The osteoporosis market is expected to grow at a compound annual growth rate of 5.4%

Marketing 264
article thumbnail

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

Pharmaceutical Technology

The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.

Marketing 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why DTC isn’t, and is, marketing

World of DTC Marketing

CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. However, DTC marketing is different, much different. So what’s the opportunity for DTC marketers?

Marketing 252
article thumbnail

COPD market expected to grow to $30.8bn in the 7MM by 2033

Pharmaceutical Technology

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is set to grow from sales of $11.5bn in 2023 to $30.8bn in 2033.

Marketing 130
article thumbnail

Leading account and intent-based sales and marketing providers and technology solutions for the pharmaceutical industry

Pharmaceutical Technology

Discover the top sales and marketing intelligence solutions tailored for the pharmaceutical industry. Download our guide to predictive analytics and data-driven insights.

Sales 130
article thumbnail

Top 20 biopharmas’ market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots

Pharmaceutical Technology

The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.

Marketing 263
article thumbnail

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.